Literature DB >> 24576206

Measurement of in vivo drug load distribution of cysteine-linked antibody-drug conjugates using microscale liquid chromatography mass spectrometry.

Shawna Mae Hengel1, Russell Sanderson, John Valliere-Douglass, Nicole Nicholas, Chris Leiske, Stephen C Alley.   

Abstract

Analysis of samples containing intact antibody-drug conjugates (ADC) using mass spectrometry provides a direct measurement of the drug-load distribution. Once dosed, the drug load distribution changes due to a combination of biological and chemical factors. Liquid chromatography-mass spectrometry (LC-MS) methods to measure the in vivo drug load distribution have been established for ADCs containing native disulfide bonds (lysine-linked or cysteine-linked). However, because of an IgG reduction step in conjugation processes, using LC-MS to analyze intact cysteine-linked ADCs requires native conditions, thus limiting sensitivity. While this limitation has been overcome at the analytical scale, to date, these methods have not been translated to a smaller scale that is required for animal or clinical doses/sampling. In this manuscript, we describe the development of ADC specific affinity capture reagents for processing in vivo samples and optimization of native LC-MS methods at a microscale. These methods are then used to detect the changing drug load distribution over time from a set of in vivo samples, representing to our knowledge the first native mass spectra of cysteine-linked ADCs from an in vivo source.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24576206     DOI: 10.1021/ac403860c

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  12 in total

1.  Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.

Authors:  M Benjamin Hock; Karen E Thudium; Montserrat Carrasco-Triguero; Nikolai F Schwabe
Journal:  AAPS J       Date:  2014-11-08       Impact factor: 4.009

2.  Quantitative collision-induced unfolding differentiates model antibody-drug conjugates.

Authors:  Yuwei Tian; Jennifer L Lippens; Chawita Netirojjanakul; Iain D G Campuzano; Brandon T Ruotolo
Journal:  Protein Sci       Date:  2018-12-22       Impact factor: 6.725

3.  Size Exclusion Chromatography Strategies and MASH Explorer for Large Proteoform Characterization.

Authors:  Timothy N Tiambeng; Zhijie Wu; Jake A Melby; Ying Ge
Journal:  Methods Mol Biol       Date:  2022

4.  A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.

Authors:  Brendan Bender; Douglas D Leipold; Keyang Xu; Ben-Quan Shen; Jay Tibbitts; Lena E Friberg
Journal:  AAPS J       Date:  2014-06-11       Impact factor: 4.009

5.  The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass.

Authors:  Amita Datta-Mannan; Hiuwan Choi; David Stokell; Jason Tang; Anthony Murphy; Aaron Wrobleski; Yiqing Feng
Journal:  AAPS J       Date:  2018-09-25       Impact factor: 4.009

Review 6.  Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates.

Authors:  Amrita V Kamath; Suhasini Iyer
Journal:  Pharm Res       Date:  2014-12-02       Impact factor: 4.200

Review 7.  Challenges and advances in the assessment of the disposition of antibody-drug conjugates.

Authors:  Amrita V Kamath; Suhasini Iyer
Journal:  Biopharm Drug Dispos       Date:  2015-06-08       Impact factor: 1.627

8.  ELISA reagent coverage evaluation by affinity purification tandem mass spectrometry.

Authors:  Scott M Henry; Elissa Sutlief; Oscar Salas-Solano; John Valliere-Douglass
Journal:  MAbs       Date:  2017-07-14       Impact factor: 5.857

9.  State-of-the-Art Native Mass Spectrometry and Ion Mobility Methods to Monitor Homogeneous Site-Specific Antibody-Drug Conjugates Synthesis.

Authors:  Evolène Deslignière; Anthony Ehkirch; Bastiaan L Duivelshof; Hanna Toftevall; Jonathan Sjögren; Davy Guillarme; Valentina D'Atri; Alain Beck; Oscar Hernandez-Alba; Sarah Cianférani
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-24

10.  Use of a charge reducing agent to enable intact mass analysis of cysteine-linked antibody-drug-conjugates by native mass spectrometry.

Authors:  Kamila J Pacholarz; Perdita E Barran
Journal:  EuPA Open Proteom       Date:  2016-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.